Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis RA Clinical Trial

Official title: A Phase 1b/2a Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy

Status Terminated

Clinical Trial Summary

Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA).

Phase 2a. To evaluate the efficacy of Efavaleukin alfa at week 12 as measured by the American College of Rheumatology 20 percent improvement criteria (ACR 20) in adult subjects with moderate to severe RA.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis RA

• NCT number: NCT03410056
• Study type: Interventional
• Source: Amgen
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: May 22, 2018
• Completion date: May 13, 2020